Ginkgo biloba does not alter clearance of flurbiprofen, a cytochrome P450-2C9 substrate

Journal of Clinical Pharmacology

Volumn 46, Issue 2, 2006, Pages 214-221

  Greenblatt, David J ^a   Von Moltke, Lisa L ^a   Luo, Yan ^a   Perloff, Elke S ^a   Horan, Kelly A ^a   Bruce, Allison ^a   Reynolds, Robyn C ^a   Harmatz, Jerold S ^a   Avula, Bharathi ^b   Khan, Ikhlas A ^b   Goldman, Peter ^c  

^a TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF MISSISSIPPI   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Cytochrome P450 2C9; Drug interactions; Flurbiprofen kinetics; Ginkgo biloba; Herbal products

Indexed keywords

AMENTOFLAVONE; ANTICOAGULANT AGENT; CYTOCHROME P450 2C9; FLURBIPROFEN; GINKGO BILOBA EXTRACT; HERBACEOUS AGENT; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; PLACEBO; PLANT EXTRACT; QUERCETIN; WARFARIN;

ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG EFFECT; DRUG ELIMINATION; DRUG HALF LIFE; DRUG METABOLISM; ENZYME INHIBITION; GINKGO BILOBA; HERB DRUG INTERACTION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; NORMAL HUMAN; PLANT LEAF; RANDOMIZED CONTROLLED TRIAL; SINGLE DRUG DOSE; TABLET FORMULATION;

ADULT; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ARYL HYDROCARBON HYDROXYLASES; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DRUG INTERACTIONS; FEMALE; FLURBIPROFEN; GINKGO BILOBA; HUMANS; MALE; PHENOTYPE; PLANT EXTRACTS; SPECTROMETRY, FLUORESCENCE;

EID: 31444439243     PISSN: 00912700     EISSN: 15524604     Source Type: Journal    
DOI: 10.1177/0091270005283465     Document Type: Article

References (33)

1. Goldman P. Herbal medicines today and the roots of modern pharmacology. Ann Intern Med. 2001;135:594-600.
2. Greenblatt DJ, von Moltke LL. Interaction of warfarin with drugs, natural substances, and foods. J Clin Pharmacol. 2005;45:127-132.
3. De Smet PA. Herbal remedies. N Engl J Med. 2002;347:2046-2056.
4. Valli G, Giardina EG. Benefits, adverse effects and drug interactions of herbal therapies with cardiovascular effects. J Am Coll Cardiol. 2002;39:1083-1095.
5. Zhou S, Gao Y, Jiang W, Huang M, Xu A, Paxton JW. Interactions of herbs with cytochrome P450. Drug Metab Rev. 2003;35:35-98.
6. Ernst E. The risk-benefit profile of commonly used herbal therapies; ginkgo, St. John's Wort, ginseng, echinacea, saw palmetto, and kava. Ann Intern Med. 2002;136:42-53.
7. Coxeter PD, McLachlan AJ, Duke CC, Roufogalis BD, Herb-drug interactions: an evidence based approach. Curr Med Chem. 2004;11:1513-1525.
8. Gilbert GJ. Ginkgo biloba, Neurology. 1997;48:1137.
9. Rowin J, Lewis SL. Spontaneous bilateral subdural hematomas associated with chronic Ginkgo biloba ingestion. Neurology. 1996;46:1775-1776.
10. Matthews MK Jr. Association of Ginkgo biloba with intracerebral hemorrhage. Neurology. 1998;50:1933-1934.
11. Yamazaki H, Shimada T. Human liver cytochrome P450 enzymes involved in the 7-hydroxylation of R- and S-warfarin enantiomers. Biochem Pharmacol. 1997;54:1195-1203.
12. He M, Kunze KL, Traeger WF. Inhibition of (S)-warfarin metabolism by sulfinpyrazone and its metabolites. Drug Metab Dispos. 1995;23:659-663.
13. Bedir E, Tatli I, Khan RA, et al. Biologically active secondary metabolites from Ginkgo biloba. J Agric Food Chem. 2002;50:3150-3155.
14. von Moltke LL, Weemhoff JL, Bedir E, et al. Inhibition of human cytochromes P450 by components of Ginkgo biloba. J Pharm Pharmacol. 2004;56:1039-1044.
15. Gaudineau C, Beckerman R, Welbourn S, Auclair K. Inhibition of human P450 enzymes by multiple constituents of the Ginkgo biloba extract. Biochem Biophys Res Commun. 2004;318:1072-1078.
16. Engelsen J, Nielsen JD, Winther K. Effect of coenzyme Q10 and Ginkgo biloba on warfarin dosage in stable, long-term warfarin treated outpatients: a randomised, double blind, placebo-crossover trial. Thromb Haemost. 2002;87:1075-1076.
17. Jiang X, Williams KM, Liauw WS, et al. Effect of ginkgo and ginger on the pharmacokinetics and pharmacodynamics of warfarin in healthy subjects. Br J Clin Pharmacol. 2005;59:425-432.
18. Uchida U, Yamada H, Li XD, et al. Effects of Ginkgo biloba on pharmacokinetics and pharmacodynamics of tolbutamide and midazolam. Paper presented at: Eighth World Congress on Clinical Pharmacology and Therapeutics; August 1-6, 2004; Brisbane, Australia.
19. Sugiyama T, Kubota Y, Shinozuka K, Yamada S, Wu J, Umegaki K. Ginkgo biloba extract modifies hypoglycemic action of tolbutamide via hepatic cytochrome P450 mediated mechanism in aged rats. Life Sci. 2004;75:1113-1122.
20. Tracy TS, Marra C, Wrighton SA, Gonzalez FJ, Korzekwa KR. Studies of flurbiprofen 4′-hydroxylation: additional evidence suggesting the sole involvement of cytochrome P450 2C9. Biochem Pharmacol. 1996;52:1305-1309.
21. Giancarlo GM, Venkatakrishnan K, Granda BW, von Moltke LL, Greenblatt DJ. Relative contributions of CYP2C9 and 2C19 to phenytoin 4-hydroxylation in vitro: inhibition by sulfaphenazole, omeprazole and ticlopidine. Eur J Clin Pharmacol. 2001;57:31-36.
22. Venkatakrishnan K, von Moltke LL, Greenblatt DJ. Human drug metabolism and the cytochromes P450: application and relevance of in vitro models. J Clin Pharmacol. 2001;41:1149-1179.
23. Venkatakrishnan K, von Moltke LL, Obach RS, Greenblatt DJ. Drug metabolism and drug interactions: application and clinical value of in vitro models. Curr Drug Metab. 2003;4:423-459.
24. Lee GR, Pieper JA, Frye RF, Hinderliter AL, Blaisdell JA, Goldstein JA. Differences in flurbiprofen pharmacokinetics between CYP2C9*1/*1, *1/*2, and *1/*3 genotypes. Eur J Clin Pharmacol. 2003;58:791-794.
25. Patel BK, Jackson SH, Swift CG, Hutt AJ. Disposition of flurbiprofen in man: influence of stereochemistry and age. Xenobiotica. 2003;33:1043-1057.
26. Frye RF, Tracy TS, Hutzler JM, et al. Flurbiprofen as a selective in vivo probe of CYP2C9 activity [abstract]. Clin Pharmacol Ther. 2000;67:109.
27. Christen Y, Maixent JM. What is Ginkgo biloba extract EGb 761? An overview-from molecular biology to clinical medicine. Cell Mol Biol (Noisy-le-grand). 2002;48:601-611.
28. Kudolo GB, Dorsey S, Blodgett J. Effect of the ingestion of Ginkgo biloba extract on platelet aggregation and urinary prostanoid excretion in healthy and type 2 diabetic subjects. Thromb Res. 2002;108:151-160.
29. van Beek TA. Chemical analysis of Ginkgo biloba leaves and extracts. J Chromatogr A. 2002;967:21-55.
30. Yu F-C, Lai S-M, Suen S-Y. Extraction of flavonoid glycosides from Ginkgo biloba leaves and their adsorption separations using hydrophobic and anion-exchange membranes. Separation Science and Technology. 2003;38:1022-1050.
31. Scalbert A, Williamson G. Dietary intake and bioavailability of polyphenols. J Nutr. 2000;130;2073S-2085S.
32. Kramer MS, Leventhal JM, Hutchinson TA, Feinstein AR. An algorithm for the operational assessment of adverse drug reactions. I. Background, description, and instructions for use. JAMA. 1979;242:623-632.
33. Naranjo CA, Busto U, Sellers EM, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther. 1981;30:239-245.